Myeloma News and Research

RSS

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

Novel, rapid and efficient assay for SARS-CoV-2 neutralizing antibodies

Researchers validate a quick, highly efficient, and automated assay to detect neutralizing antibodies against SARS-CoV-2.

7 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

MD Anderson and Yingli Pharma announce strategic alliance to advance many oncology programs

The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.

20 Jan 2022

Metabolic vulnerabilities in malignant cells may lead to new breast cancer therapies

Metabolic differences could explain why some metastatic breast cancer cells rapidly generate tumors after migrating from primary tumors to the brain, while others linger for months or years before forming these secondary tumors, UT Southwestern scientists report in a new study.

12 Jan 2022

Efficacy of COVID-19 convalescent plasma therapy in patients with hematological malignancies and COVID-19

Scientists recently demonstrated the efficacy of COVID-19 convalescent plasma therapy in improving the survival rate among patients with B-cell lymphoid malignancy and COVID-19.

5 Jan 2022

$Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma$

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

21 Dec 2021

Study provides a more effective treatment approach to preventing graft-versus-host-disease

A new study led by UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease (GVHD), an inflammatory condition that develops in patients after their allogeneic hematopoietic stem cell transplantation (allo-HSCT).

16 Dec 2021

Gene key to excessive cell proliferation could be a potential target for fatal pulmonary hypertension

A gene that is overexpressed in some aggressive cancers also appears to be key to the excessive cell proliferation that thickens the walls of pulmonary arteries and ultimately causes the right ventricle of the heart to fail, scientists report.

16 Dec 2021

COVID-19 vaccines offer protection for multiple myeloma patients, but lesser than other cancer survivors

For patients with the blood cancer multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection but to a far lower degree than the general population of cancer survivors, a new study by Dana-Farber Cancer Institute investigators shows.

13 Dec 2021

Large study reveals increased rates of myeloma precursor condition in high-risk groups

The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.

13 Dec 2021

Clinical studies show enhanced responses for lymphoma patients treated with axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

12 Dec 2021

Potentially serious side effect reported after CAR-T cell therapy for multiple myeloma

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.

11 Dec 2021

NYU Langone opens new state-of-the-art center to treat patients with blood cancers

NYU Langone Health's Laura and Isaac Perlmutter Cancer Center opened a new state-of-the-art center to treat people with blood cancers, including leukemia, lymphoma, and multiple myeloma.

29 Nov 2021

Combination of two targeted drugs shows "clinically meaningful" activity in some malignant brain tumors

A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

25 Nov 2021

Study shows vaccinated multiple myeloma patients at greater risk of breakthrough SARS-CoV-2 infections

Researchers recently published a study assessing the risks of patients with MM to breakthrough infections after completing their vaccination schedule compared to those without any form of cancer.

25 Nov 2021

Exosomes involved in the progression of breast cancer in patients with obesity, diabetes

Obesity, insulin resistance and Type 2 diabetes are risk factors for breast cancer in post-menopausal women. The metabolic and inflammatory complications of obesity have a role in the formation of cancer.

24 Nov 2021

Red blood cell distribution width as a biomarker for COVID-19

A review highlights the prospects and challenges of RDW as a predictive biomarker for viral infections, with a special focus on COVID-19 and hepatitis.

22 Nov 2021

bit.bio appoints Kathryn Corzo as Chief Operating Officer

Cell coding company bit.bio today announces the key appointment of Kathryn Corzo as Chief Operating Officer. She started in the role on 1 November 2021.

From bit.bio 19 Nov 2021

Researchers identify never-before-defined subtypes of a blood cancer

Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.

17 Nov 2021